RecruitingPhase 2NCT05748145
Metronidazole as Preoperative Therapy in CRC / FusoMetro-001
Preoperative Treatment With Metronidazole to Evaluate the Efficacy in Reducing Fusobacterium Nucleatum Tumor Colonization in Patients With Colorectal Cancer (CRC): a Proof-of-concept Trial
Sponsor
Oncology Institute of Southern Switzerland
Enrollment
40 participants
Start Date
Sep 11, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Written informed consent according to ICH/GCP regulations before registration.
- Age ≥ 18 years old
- Untreated, primary colorectal adenocarcinoma (\> 15 cm from the anal verge)
- Colonoscopy with endoscopic biopsy for disease confirmation and correlative studies.
- Candidates for surgical resection prior to administration of any therapy.
Exclusion Criteria12
- Insufficient material on the tissue biopsy to be left in the archives of the Cantonal Institute of Pathology for further evaluations/analyses
- Known prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives
- Oral or parenteral antibiotic therapy within the six weeks prior to enrolment
- Emergency surgery (planned within less than 14 days), where no opportunity to administer preoperative oral antibiotics exists
- Other malignant disease within 5 years prior to study enrollment, except basocellular or squamous skin cancer and carcinoma in situ cervices uteri
- Any previous anticancer treatment prior resection
- Women who are pregnant or breast feeding
- Fertile women or men who do not use safe contraception during the study period
- Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.),
- Inability to consent and follow the procedures of the study e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- Participation in another study with investigational drug within the 30 days preceding and during the present study,
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment, affect patient compliance or place the patient at high risk from treatment-related complications
Interventions
DRUGMetronidazole Oral
Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05748145
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations